Ian Haydock

Tokyo

Editor-in-Chief, Asia-Pacific at Scrip

Editor-in-Chief, Asia-Pacific at The Pink Sheet

Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.

Featured in: Favicon

informa.com (+5) Favicon

pharmamedtechbi.com Favicon

biospectrumasia.com Favicon

pharmaceuticalmanufacturer.media Favicon

citeline.com (+1)

Articles

Quick Listen: Scrip’s Five Must-Know Things

5 days ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project. Weekly audio roundup of selected content from Scrip's global team
Quick Listen: Scrip’s Five Must-Know Things

1 week ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership. Weekly audio roundup of selected content from Scrip's global team
Citeline Japan Awards 2025 - Enter Now!

2 weeks ago | insights.citeline.com | Ian Haydock |Lisa Takagi

Citeline Japan Awards 2025 - Enter Now!14 July Deadline The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available. 14 July deadline for entries for the Citeline Japan Awards 2025 • Source: Citeline
Quick Listen: Scrip’s Five Must-Know Things

2 weeks ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy. Weekly audio roundup of selected content from Scrip's global team
Quick Listen: Scrip’s Five Must-Know Things

3 weeks ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma. Weekly audio roundup of selected content from Scrip's global team.
Quick Listen: Scrip’s Five Must-Know Things

1 month ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth. Weekly audio roundup of selected content from Scrip's global team
Quick Listen: Scrip’s Five Must-Know Things

1 month ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls. Weekly audio roundup of selected content from Scrip's global team
Multiple Launches Help Lilly’s Japan Growth

1 month ago | insights.citeline.com | Ian Haydock

Multiple Launches Help Lilly’s Japan Growth Building Alzheimer’s, Obesity Presence Lilly saw solid growth for its business in Japan last year on the back of several new launches and it building its obesity and Alzheimer's portfolios in the country. Growth For Lilly's Japan Operation Helped By Multiple Launches • Source: Shutterstock
Quick Listen: Scrip’s Five Must-Know Things

1 month ago | insights.citeline.com | Ian Haydock

Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology. weekly audio roundup of selected content from Scrip's global team
Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

1 month ago | insights.citeline.com | Ian Haydock

Shionogi In $1bn Deal For Japan Tobacco’s Pharma OpsMid-Tier Consolidation With ToriiMid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business in Japan, in bid to build sales reach and manufacturing. Japanese mid-sized pharma firms to merge (Shutterstock)